S100A16 is a prognostic marker for colorectal cancer.

BACKGROUND: S100 is a superfamily of calcium-binding proteins that regulate multiple biological processes and are involved in many diseases. S100A16 has recently been identified to be involved in several cancers such as bladder cancer, lung cancer, and oral squamous cell carcinoma. However, the role of S100A16 expression in the colorectal cancer (CRC) has not been investigated. METHODS: S100A16 protein expression was detected by immunohistochemistry in 296 cases of CRC. Kaplan-Meier survival analysis and Cox regression analysis were performed to evaluate the prognostic significance of S100A16. RESULT: The results showed that the overall survival (OS) of patients with low membrane S100A16 expression was significantly shorter than patients with high expression (P < 0.05). Chi-square analysis showed that S100A16 expression had a positive correlation with tumor grade (P = 0.02). Multivariate analysis identified membrane S100A16 expression as an independent prognostic marker for OS in CRC patients. (P < 0.05). Univariate analysis showed no significant association between cytoplasmic/nuclear S100A16 expression and OS. CONCLUSION: Membrane S100A16 is associated with the prognosis of CRC patients, indicating that S100A16 may be a potential prognostic biomarker and therapeutic target for CRC.

FBXO2, a novel marker for metastasis in human gastric cancer.

FBXO2 belongs to the F-box family of proteins, is a cytoplasmic protein and ubiquitin ligase F-box protein with specificity for high-mannose glycoproteins. Recently published studies indicate that other members of the F-box family, such as SKP2 and FBXW7, are involved in the development of gastric cancer. The role of FBXO2 in the process of tumorigenesis, including gastric cancer, is still unknown. In this study, we show that the level of FBXO2 is highly correlated with lymph node metastasis, and that overall survival (OS) of patients with high FBXO2 expression is significantly shorter than patients with low FBXO2 expression. FBXO2 promoted the proliferation and migration of human gastric cancer cells, whereas knockdown of FBXO2 by siRNA led to a decrease in those activities. Down-regulating FBXO2 reduced epithelial-mesenchymal transition (EMT) in gastric cancer cells, with increased expression of E-cadherin and decreased expression of N-cadherin and vimentin. In summary, our findings suggest that FBXO2-regulated EMT led to carcinogenicity in gastric cancer and may be a novel target in the diagnosis and treatment of gastric cancer.